Novartis Stock Surged After Oral MS Pill Passed Two Late-Stage Trials
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novartis announced that its oral multiple sclerosis medication, remibrutinib, succeeded in two large studies. The results have led to a surge in Novartis stock, reflecting investor confidence in the drug's potential impact on the market.
Notably, Novartis revealed that remibrutinib wasn’t associated with significant adverse effects, which could enhance its appeal among patients and healthcare providers.
Novartis
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Novartis stock surged after its oral multiple sclerosis pill passed two late-stage trials”
quartz — Novartis stock surged after its oral multiple sclerosis pill passed two late-stage trials“<figure><div><img”
biopharma dive — Novartis says MS pill succeeds in two large studies